ABSTRACT

Background

Patients receiving haemodialysis via a central venous catheter (HD-CVC) have been shown to have an increased risk of all-cause mortality. It is unclear whether death from dialysis withdrawal is associated with the high mortality risk observed in patients initiated on HD-CVC.

Methods

Using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, we examined the association between initial dialysis access [HD-CVC, haemodialysis via arteriovenous fistula (HD-AVF), and peritoneal dialysis (PD) via PD catheter (PD-PDC)] and death from dialysis withdrawal in adult patients starting dialysis in Australia between 2005 and 2022, analysed by time-stratified adjusted Cox regression with propensity score-matched cohorts.

Results

Of 47 412 incident patients followed for a median of 2.65 years (interquartile range 1.19–4.87), 8170 (17%) died from dialysis withdrawal. Compared with patients initiated on HD-AVF, patients initiated on HD-CVC were more likely to experience death from dialysis withdrawal in the first 3 years after dialysis initiation, but not after 3 years [adjusted hazard ratios 2.43 (95% confidence interval 1.95–3.02), 2.06 (1.67–2.53), 1.57 (1.40–1.76), and 1.06 (0.97–1.15) for 0–6 months, >6–12 months, >1–3 years, and >3 years after dialysis initiation, respectively]. Comparison between patients initiated on HD-CVD and PD-PDC showed similar estimates. No difference in withdrawal risk was observed between patients initiated on HD-AVF and PD-PDC.

Conclusions

Patients initiated on HD-CVC were twice as likely to experience early death from dialysis withdrawal compared with patients who had initiated dialysis with HD-AVF or PD-PDC. The increased risks diminished over time and were not observed after 3 years on dialysis.

KEY LEARNING POINTS

What was known:

  • Death from dialysis withdrawal is one of the most common causes of death in patients receiving maintenance dialysis.

  • Patients initiated on haemodialysis via central venous catheter (HD-CVC) had greater all-cause mortality, compared with patients who initiated on haemodialysis via arteriovenous fistula (HD-AVF).

  • Current literature assessing dialysis withdrawal in patients receiving dialysis via different types of dialysis access is limited.

This study adds:

  • Patients initiated on HD-CVC were twice as likely to experience dialysis withdrawal in the first 12 months after dialysis initiation, compared with other types of dialysis access.

  • The increased risk of dialysis withdrawal in patients initiated on HD-CVC diminished over time. There was no association observed between initial type of dialysis access and dialysis withdrawal 3 years post-dialysis initiation.

Potential impact:

  • Recognizing the risk of early dialysis withdrawal in patients initiated on HD-CVD can better inform the shared decision-making process when selecting an appropriate treatment modality in patients with kidney failure.

  • Delaying conversion from HD-CVC to HD-AVF or peritoneal dialysis (PD) via PD catheter may be appropriate in selected patients. Further studies are needed to assess the risks and benefits of early dialysis access conversion, especially in the first 12 months after dialysis initiation.

  • In patients to be initiated on dialysis via HD-CVC, early involvement of kidney supportive care or palliative care teams may assist the shared decision-making in the selection of dialysis versus non-dialysis pathways and may alleviate symptoms associated with kidney failure and dialysis treatment which could potentially limit withdrawal from dialysis.

INTRODUCTION

Dialysis withdrawal is one of the most common causes of death in patients receiving dialysis [1–3]. Reasons for dialysis withdrawal include life-limiting comorbidities, lack of dialysis access, and psychosocial preferences [4]. A previous Australian cohort study showed that the initial dialysis access type was associated with the highest risk of early dialysis withdrawal, more than age or comorbidities. Patients who commenced haemodialysis via a central venous catheter (HD-CVC) were twice as likely to experience dialysis withdrawal in the first year of dialysis initiation compared with patients who started haemodialysis via autologous arteriovenous fistula (HD-AVF) [5]. However, this association may be explained by differences in patient characteristics that are known to be associated with mortality [6]. The long-term association of the initial dialysis access type with dialysis withdrawal is also uncertain.

Traditionally, a ‘fistula first’ approach was the recommendation, based on the 2001 National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines [7]. However, the notion of ‘fistula first policy’ has been challenged in recent times, especially in elderly patients with limited life expectancy and high risks of arteriovenous fistula (AVF) dysfunction and complications [8–10]. As older and frailer patients are more likely to commence HD-CVC, they may also be more ambivalent regarding long-term dialysis [10, 11]. Moreover, prior observational studies have suggested that female patients and patients referred to a nephrologist just prior to dialysis initiation are more likely to opt for dialysis withdrawal [2, 5, 12–14]. A better understanding of the association between dialysis access types and dialysis withdrawal could help facilitate the shared decision-making process, especially at the time of dialysis modality selection and the subsequent end-of-life care [8].

The aims of this study were two-fold. First, we examined the associations between types of dialysis access with dialysis withdrawal. Second, we examined whether the association between dialysis access types and dialysis withdrawal was modified by age, sex, or late nephrologist referral.

MATERIALS AND METHODS

Study design and study cohort

This was a retrospective, registry-based, observational cohort study. Adult patients (aged 18 years and over) commencing maintenance dialysis for kidney failure for the first time in Australia between 1 January 2005 and 31 December 2022 were included using data from the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry. Patients from New Zealand were excluded due to the lack of local data on residential postcode and socioeconomic status. The follow-up period was censored at death, kidney transplantation, loss to follow-up, or 31 December 2022, whichever occurred first. The conduct of this study was approved by the University of Western Australia Human Research Ethics Committee (reference 021/ET000360), Australia. The study was conducted in accordance with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [15].

Data collection

Baseline demographic and dialysis characteristics at the time of kidney replacement therapy initiation were extracted from the ANZDATA Registry, including age, sex, ethnicity, body mass index (BMI), geographical location (urban, regional, and remote), socio-economic status (SES; measured by Index of Relative Socio-economic Advantage and Disadvantage using postcode and categorized into tertiles) [16], era (categorized as 2005–10, 2011–16, and 2017–22), smoking status, comorbid medical conditions (presence or absence of coronary artery disease, peripheral vascular disease, cerebrovascular disease, chronic lung disease, diabetes mellitus, and cancer), late nephrologist referral (defined as <3 months before dialysis initiation), primary cause of kidney failure (diabetic kidney disease, glomerulonephritis, hypertensive nephrosclerosis, cystic kidney disease, and other causes) and prior pre-emptive kidney transplantation. Baseline centre-level characteristics included transplant centre and centre size [calculated as the annual number of patients on incident haemodialysis, peritoneal dialysis (PD) or either at the time of dialysis initiation]. Centre size was divided into quartiles by patient number and grouped into three categories by combining the second and third quartiles. The dialysis centre was defined as the centre where dialysis was initiated but did not consider the potential transfer to alternative dialysis centre(s) over time.

Exposure factor

Dialysis access type at the initiation of dialysis was categorized into three groups: HD-AVF (autologous AVF), HD-CVC (tunnelled and non-tunnelled CVC), and PD-PDC (PD catheter). Patients initiated on PD were assumed to have initiated dialysis with a PD catheter. Patients initiated on haemodialysis without dialysis access reported at first haemodialysis were excluded. Patients initiated on haemodialysis via arteriovenous graft (HD-AVG) were excluded in the primary analysis due to small sample size and potentially different patient phenotype compared with patients on HD-AVF. In the sensitivity analysis, patients initiated on HD-AVG were included in combination with HD-AVF as a single cohort. Initial haemodialysis access was defined as the access at first haemodialysis reported in the ANZDATA annual survey.

Clinical outcomes

The primary outcome was death from dialysis withdrawal. Death from dialysis withdrawal included psychosocial reasons, life-limiting comorbid medical conditions (cardiovascular disease, cerebrovascular disease, peripheral vascular disease, or cancer), and dialysis access difficulties. The causes of withdrawal were pre-specified in the ANZDATA Registry survey [17].

Statistical analysis

The baseline data were expressed as numbers (proportion) for categorical data, mean ± standard deviation (SD) for normally distributed continuous data, and median [interquartile range (IQR)] for non-normally distributed continuous data. The all-cause and withdrawal-related mortality rates were expressed as events [95% confidence interval (CI)] per 1000 patient-years. Patients initiated on HD-AVF, HD-CVC, and PD-PDC were matched 1:1 separately in pairs using the nearest neighbour within a calliper width of 0.01 of the propensity score with no replacement. Propensity scores were calculated using multivariable logistic regression matching age, sex, ethnicity, BMI, late nephrology referral, comorbid medical conditions (coronary artery disease, peripheral vascular disease, cerebrovascular disease, chronic lung disease, diabetes mellitus, and cancer), primary kidney disease, geographical location, era, and SES. These factors were selected because of the established associations with dialysis withdrawal and/or all-cause mortality in patients maintained on dialysis [5, 18, 19].

The associations between dialysis access and dialysis withdrawal for matched cohorts were examined using adjusted Cox proportional hazard (PH) regression via model building, expressed as hazard ratios (HRs) with 95% CI. The starting time in all models was time of dialysis initiation. The PH assumptions of all models were checked graphically by plotting the Schoenfeld residuals. As PH assumptions were violated in all models, the time period between dialysis initiation and outcome event was divided into 0–6 months, >6–12 months, >1–3 years, and >3 years. Collinearity between covariates was checked by a correlation matrix of coefficients. Model 1 was univariate analysis, and Model 2 included non-modifiable factors. Medical factors were added in Model 3, and social factors were added in Model 4. Cluster effects were examined in Model 5 using the γ-distributed Cox shared frailty model, considering initial dialysis centre as the cluster. Model 3 was considered as the final model due to the lack of association with social factors and the lack of cluster effects. Flexible parametric PH analyses were conducted using the method described by Royston and Parmar [20] and plotted as continuous adjusted HRs during the follow-up period, up to 10 years post-dialysis initiation.

Competing risk regression analyses were conducted using the method described by Fine and Gray [21], expressed as subdistribution hazard ratios (SHRs). Covariates included in the competing risk models were identical to those included in Model 3 of the Cox regression models. Kidney transplantation and causes of death other than dialysis withdrawal were considered as competing events. Considering the potential differences in dialysis access outcomes based on age, sex, and late referral, pre-specified two-way interactions between vascular access and these variables were examined a priori using Model 3. Sensitivity analysis was conducted combining HD-AVG and HD-AVF as a single group. Multiple comparisons were assessed using the Benjamini–Hochberg procedure with 95% false discovery rate (FDR) confidence intervals. Statistical evaluation was performed using SPSS version 28 (IBM, Armonk, NY, USA) and STATA version IC 15.1 (StataCorp, College Station, TX, USA) statistical programs. P-values <0.05 were considered statistically significant.

RESULTS

The study cohort comprised 47 412 incident patients who commenced dialysis between 2005 and 2022 in Australia, after excluding 374 (0.8%) patients with missing initial dialysis access data and 580 (1.2%) patients who had initiated on haemodialysis using AVG (Fig. 1). The patient follow-up period was 165 126 person-years with median follow-up time of 2.65 (IQR 1.19–4.87) years. Among all incident patients, 14 298 (30%) patients commenced with HD-AVF, 20 620 (44%) patients commenced with HD-CVC, and 12 494 (26%) patients commenced with PD-PDC. The mean ± SD age at dialysis initiation was 61.1 ± 15.1 years. Compared with patients who were initiated on PD-PDC or HD-AVF, patients who were commenced on HD-CVC were more likely to experience late referral (35% vs 11% for PD-PDC and 6% for HD-AVF, < 0.001) with a greater proportion with comorbid medical conditions at the time of dialysis initiation (Table 1). Supplementary Table 1 shows the baseline characteristics of the study cohort by the propensity score-matched pairs. Missing data are shown in Supplementary Tables 1 and 2.

Patient flowchart for adult incident dialysis patients in Australia between 2005 and 2022.
Figure 1:

Patient flowchart for adult incident dialysis patients in Australia between 2005 and 2022.

Table 1:

Baseline characteristics of adult patients commencing dialysis in Australia between 2005 and 2022.

 Descriptive statistics
CharacteristicsHaemodialysis via autologous AVFHaemodialysis via CVCPeritoneal dialysisOverall
Patient-level characteristics
Number of patients14 29820 62012 49447 412
Age starting dialysis (years, mean ± SD)62.7 (14.0)60.9 (15.8)59.7 (15.2)61.1 (15.1)
Men (n, %)9419 (66)12 486 (61)7682 (62)29 587 (62)
Ethnicity (n, %)
 Caucasians10 456 (74)14 325 (70)8415 (68)33 196 (71)
 Asians1090 (8)1771 (9)2148 (17)5009 (11)
 Indigenousa1911 (13)3418 (17)1066 (9)6395 (14)
 Others728 (5)942 (5)767 (6)2437 (5)
BMI (mean ± SD)29.8 (7.4)28.5 (7.8)27.3 (5.7)28.6 (7.2)
BMI categories (n, %)
 Underweight251 (2)733 (4)342 (3)1326 (3)
 Normal3543 (25)6507 (32)4157 (34)14207 (31)
 Overweight4368 (31)6093 (30)4402 (36)14863 (32)
 Obese5895 (42)6789 (34)3457 (28)16141 (35)
Dialysis modality (n, %)
 Peritoneal dialysis12 494 (100)12 94 (26)
 Haemodialysis
  Facility haemodialysis13 819 (97)20 578 (99.8)34 397 (73)
  Home haemodialysis479 (3)42 (0.2)521 (1)
Smoking status (n, %)
 Non-smoker6690 (48)9568 (47)6311 (51)22 569 (48)
 Current smoker1570 (11)2784 (14)1323 (11)5677 (12)
 Ex-smoker5797 (41)7980 (39)4728 (38)18 505 (40)
Comorbidities
 Chronic lung disease (n, %)1705 (12)3053 (15)1069 (9)5827 (12)
 Coronary artery disease (n, %)4637 (33)7426 (36)3284 (26)15 347 (33)
 Peripheral vascular disease (n, %)2310 (16)3964 (19)1647 (13)7921 (17)
 Cerebrovascular disease (n, %)1434 (10)2391 (12)1099 (9)4924 (10)
 Diabetes mellitus (n, %)
  Type 1519 (4)983 (5)711 (6)2213 (5)
  Type 26817 (48)9920 (48)4905 (39)21 642 (46)
 Cancer (n, %)1743 (12)2688 (13)1056 (9)5487 (12)
Late nephrologist referral (n, %)799 (6)7215 (35)1294 (11)9308 (20)
Cause of kidney failure (n, %)
 Diabetic nephropathy5573 (39)8110 (40)4280 (34)17 963 (38)
 Glomerular kidney disease2584 (18)3713 (18)2983 (24)9280 (20)
 Hypertension nephrosclerosis2048 (14)2855 (14)1817 (15)6720 (14)
 Familial/genetic kidney disease1481 (10)687 (3)1063 (9)3231 (7)
 Tubulointerstitial disease1310 (9)1675 (8)1121 (9)4106 (9)
 Others1214 (9)3431 (17)1173 (9)5818 (12)
Geographical location (n, %)
 Urban9371 (66)13 421 (66)8739 (70)31 531 (67)
 Regional3900 (28)5411 (27)3186 (26)12 497 (27)
 Remote909 (6)1602 (8)499 (4)3010 (6)
Socio-economic status (n, %)
 Low4258 (30)6333 (31)3909 (32)14 500 (31)
 Mid5444 (38)7715 (38)4707 (38)17 866 (38)
 High4469 (32)6379 (31)3804 (31)14 651 (31)
State/territory at dialysis initiation (n, %)
 New South Wales3685 (26)6027 (29)4591 (37)14 303 (30)
 Queensland2933 (21)4156 (20)2383 (19)9472 (20)
 Victoria3770 (26)4678 (23)2937 (24)11 385 (24)
 Australian Capital Territory301 (2)518 (3)162 (1)981 (2)
 South Australia1316 (9)1246 (6)816 (7)3378 (7)
 Western Australia1404 (10)2573 (13)1216 (10)5193 (11)
 Northern Territory605 (4)1017 (5)159 (1)1781 (4)
 Tasmania284 (2)405 (2)230 (2)919 (2)
Era (n, %)
 2005–103957 (28)6249 (30)3318 (27)13 524 (29)
 2011–164702 (33)6246 (30)4244 (34)15 192 (32)
 2017–225639 (39)8125 (40)4932 (40)18 696 (39)
Pre-emptive transplant (n, %)78 (0.5)125 (0.6)91 (0.7)294 (0.6)
Centre-level characteristics
Number of centres10110467106
Transplant centre (n, %)17 (17)17 (16)16 (24)18 (17)
Centre size (median, IQR)
 Incidence dialysis patient/year57 (31–101)62 (38–101)78 (45–113)64 (38–106)
 Incidence PD patient/year13 (5–27)15 (6–27)22 (7–39)16 (7–30)
 Incidence HD patient/year44 (24–70)46 (28–71)48 (31–70)46 (28–70)
 Descriptive statistics
CharacteristicsHaemodialysis via autologous AVFHaemodialysis via CVCPeritoneal dialysisOverall
Patient-level characteristics
Number of patients14 29820 62012 49447 412
Age starting dialysis (years, mean ± SD)62.7 (14.0)60.9 (15.8)59.7 (15.2)61.1 (15.1)
Men (n, %)9419 (66)12 486 (61)7682 (62)29 587 (62)
Ethnicity (n, %)
 Caucasians10 456 (74)14 325 (70)8415 (68)33 196 (71)
 Asians1090 (8)1771 (9)2148 (17)5009 (11)
 Indigenousa1911 (13)3418 (17)1066 (9)6395 (14)
 Others728 (5)942 (5)767 (6)2437 (5)
BMI (mean ± SD)29.8 (7.4)28.5 (7.8)27.3 (5.7)28.6 (7.2)
BMI categories (n, %)
 Underweight251 (2)733 (4)342 (3)1326 (3)
 Normal3543 (25)6507 (32)4157 (34)14207 (31)
 Overweight4368 (31)6093 (30)4402 (36)14863 (32)
 Obese5895 (42)6789 (34)3457 (28)16141 (35)
Dialysis modality (n, %)
 Peritoneal dialysis12 494 (100)12 94 (26)
 Haemodialysis
  Facility haemodialysis13 819 (97)20 578 (99.8)34 397 (73)
  Home haemodialysis479 (3)42 (0.2)521 (1)
Smoking status (n, %)
 Non-smoker6690 (48)9568 (47)6311 (51)22 569 (48)
 Current smoker1570 (11)2784 (14)1323 (11)5677 (12)
 Ex-smoker5797 (41)7980 (39)4728 (38)18 505 (40)
Comorbidities
 Chronic lung disease (n, %)1705 (12)3053 (15)1069 (9)5827 (12)
 Coronary artery disease (n, %)4637 (33)7426 (36)3284 (26)15 347 (33)
 Peripheral vascular disease (n, %)2310 (16)3964 (19)1647 (13)7921 (17)
 Cerebrovascular disease (n, %)1434 (10)2391 (12)1099 (9)4924 (10)
 Diabetes mellitus (n, %)
  Type 1519 (4)983 (5)711 (6)2213 (5)
  Type 26817 (48)9920 (48)4905 (39)21 642 (46)
 Cancer (n, %)1743 (12)2688 (13)1056 (9)5487 (12)
Late nephrologist referral (n, %)799 (6)7215 (35)1294 (11)9308 (20)
Cause of kidney failure (n, %)
 Diabetic nephropathy5573 (39)8110 (40)4280 (34)17 963 (38)
 Glomerular kidney disease2584 (18)3713 (18)2983 (24)9280 (20)
 Hypertension nephrosclerosis2048 (14)2855 (14)1817 (15)6720 (14)
 Familial/genetic kidney disease1481 (10)687 (3)1063 (9)3231 (7)
 Tubulointerstitial disease1310 (9)1675 (8)1121 (9)4106 (9)
 Others1214 (9)3431 (17)1173 (9)5818 (12)
Geographical location (n, %)
 Urban9371 (66)13 421 (66)8739 (70)31 531 (67)
 Regional3900 (28)5411 (27)3186 (26)12 497 (27)
 Remote909 (6)1602 (8)499 (4)3010 (6)
Socio-economic status (n, %)
 Low4258 (30)6333 (31)3909 (32)14 500 (31)
 Mid5444 (38)7715 (38)4707 (38)17 866 (38)
 High4469 (32)6379 (31)3804 (31)14 651 (31)
State/territory at dialysis initiation (n, %)
 New South Wales3685 (26)6027 (29)4591 (37)14 303 (30)
 Queensland2933 (21)4156 (20)2383 (19)9472 (20)
 Victoria3770 (26)4678 (23)2937 (24)11 385 (24)
 Australian Capital Territory301 (2)518 (3)162 (1)981 (2)
 South Australia1316 (9)1246 (6)816 (7)3378 (7)
 Western Australia1404 (10)2573 (13)1216 (10)5193 (11)
 Northern Territory605 (4)1017 (5)159 (1)1781 (4)
 Tasmania284 (2)405 (2)230 (2)919 (2)
Era (n, %)
 2005–103957 (28)6249 (30)3318 (27)13 524 (29)
 2011–164702 (33)6246 (30)4244 (34)15 192 (32)
 2017–225639 (39)8125 (40)4932 (40)18 696 (39)
Pre-emptive transplant (n, %)78 (0.5)125 (0.6)91 (0.7)294 (0.6)
Centre-level characteristics
Number of centres10110467106
Transplant centre (n, %)17 (17)17 (16)16 (24)18 (17)
Centre size (median, IQR)
 Incidence dialysis patient/year57 (31–101)62 (38–101)78 (45–113)64 (38–106)
 Incidence PD patient/year13 (5–27)15 (6–27)22 (7–39)16 (7–30)
 Incidence HD patient/year44 (24–70)46 (28–71)48 (31–70)46 (28–70)

aIndigenous—Aboriginal and Torres Strait Islander, Polynesian.

Table 1:

Baseline characteristics of adult patients commencing dialysis in Australia between 2005 and 2022.

 Descriptive statistics
CharacteristicsHaemodialysis via autologous AVFHaemodialysis via CVCPeritoneal dialysisOverall
Patient-level characteristics
Number of patients14 29820 62012 49447 412
Age starting dialysis (years, mean ± SD)62.7 (14.0)60.9 (15.8)59.7 (15.2)61.1 (15.1)
Men (n, %)9419 (66)12 486 (61)7682 (62)29 587 (62)
Ethnicity (n, %)
 Caucasians10 456 (74)14 325 (70)8415 (68)33 196 (71)
 Asians1090 (8)1771 (9)2148 (17)5009 (11)
 Indigenousa1911 (13)3418 (17)1066 (9)6395 (14)
 Others728 (5)942 (5)767 (6)2437 (5)
BMI (mean ± SD)29.8 (7.4)28.5 (7.8)27.3 (5.7)28.6 (7.2)
BMI categories (n, %)
 Underweight251 (2)733 (4)342 (3)1326 (3)
 Normal3543 (25)6507 (32)4157 (34)14207 (31)
 Overweight4368 (31)6093 (30)4402 (36)14863 (32)
 Obese5895 (42)6789 (34)3457 (28)16141 (35)
Dialysis modality (n, %)
 Peritoneal dialysis12 494 (100)12 94 (26)
 Haemodialysis
  Facility haemodialysis13 819 (97)20 578 (99.8)34 397 (73)
  Home haemodialysis479 (3)42 (0.2)521 (1)
Smoking status (n, %)
 Non-smoker6690 (48)9568 (47)6311 (51)22 569 (48)
 Current smoker1570 (11)2784 (14)1323 (11)5677 (12)
 Ex-smoker5797 (41)7980 (39)4728 (38)18 505 (40)
Comorbidities
 Chronic lung disease (n, %)1705 (12)3053 (15)1069 (9)5827 (12)
 Coronary artery disease (n, %)4637 (33)7426 (36)3284 (26)15 347 (33)
 Peripheral vascular disease (n, %)2310 (16)3964 (19)1647 (13)7921 (17)
 Cerebrovascular disease (n, %)1434 (10)2391 (12)1099 (9)4924 (10)
 Diabetes mellitus (n, %)
  Type 1519 (4)983 (5)711 (6)2213 (5)
  Type 26817 (48)9920 (48)4905 (39)21 642 (46)
 Cancer (n, %)1743 (12)2688 (13)1056 (9)5487 (12)
Late nephrologist referral (n, %)799 (6)7215 (35)1294 (11)9308 (20)
Cause of kidney failure (n, %)
 Diabetic nephropathy5573 (39)8110 (40)4280 (34)17 963 (38)
 Glomerular kidney disease2584 (18)3713 (18)2983 (24)9280 (20)
 Hypertension nephrosclerosis2048 (14)2855 (14)1817 (15)6720 (14)
 Familial/genetic kidney disease1481 (10)687 (3)1063 (9)3231 (7)
 Tubulointerstitial disease1310 (9)1675 (8)1121 (9)4106 (9)
 Others1214 (9)3431 (17)1173 (9)5818 (12)
Geographical location (n, %)
 Urban9371 (66)13 421 (66)8739 (70)31 531 (67)
 Regional3900 (28)5411 (27)3186 (26)12 497 (27)
 Remote909 (6)1602 (8)499 (4)3010 (6)
Socio-economic status (n, %)
 Low4258 (30)6333 (31)3909 (32)14 500 (31)
 Mid5444 (38)7715 (38)4707 (38)17 866 (38)
 High4469 (32)6379 (31)3804 (31)14 651 (31)
State/territory at dialysis initiation (n, %)
 New South Wales3685 (26)6027 (29)4591 (37)14 303 (30)
 Queensland2933 (21)4156 (20)2383 (19)9472 (20)
 Victoria3770 (26)4678 (23)2937 (24)11 385 (24)
 Australian Capital Territory301 (2)518 (3)162 (1)981 (2)
 South Australia1316 (9)1246 (6)816 (7)3378 (7)
 Western Australia1404 (10)2573 (13)1216 (10)5193 (11)
 Northern Territory605 (4)1017 (5)159 (1)1781 (4)
 Tasmania284 (2)405 (2)230 (2)919 (2)
Era (n, %)
 2005–103957 (28)6249 (30)3318 (27)13 524 (29)
 2011–164702 (33)6246 (30)4244 (34)15 192 (32)
 2017–225639 (39)8125 (40)4932 (40)18 696 (39)
Pre-emptive transplant (n, %)78 (0.5)125 (0.6)91 (0.7)294 (0.6)
Centre-level characteristics
Number of centres10110467106
Transplant centre (n, %)17 (17)17 (16)16 (24)18 (17)
Centre size (median, IQR)
 Incidence dialysis patient/year57 (31–101)62 (38–101)78 (45–113)64 (38–106)
 Incidence PD patient/year13 (5–27)15 (6–27)22 (7–39)16 (7–30)
 Incidence HD patient/year44 (24–70)46 (28–71)48 (31–70)46 (28–70)
 Descriptive statistics
CharacteristicsHaemodialysis via autologous AVFHaemodialysis via CVCPeritoneal dialysisOverall
Patient-level characteristics
Number of patients14 29820 62012 49447 412
Age starting dialysis (years, mean ± SD)62.7 (14.0)60.9 (15.8)59.7 (15.2)61.1 (15.1)
Men (n, %)9419 (66)12 486 (61)7682 (62)29 587 (62)
Ethnicity (n, %)
 Caucasians10 456 (74)14 325 (70)8415 (68)33 196 (71)
 Asians1090 (8)1771 (9)2148 (17)5009 (11)
 Indigenousa1911 (13)3418 (17)1066 (9)6395 (14)
 Others728 (5)942 (5)767 (6)2437 (5)
BMI (mean ± SD)29.8 (7.4)28.5 (7.8)27.3 (5.7)28.6 (7.2)
BMI categories (n, %)
 Underweight251 (2)733 (4)342 (3)1326 (3)
 Normal3543 (25)6507 (32)4157 (34)14207 (31)
 Overweight4368 (31)6093 (30)4402 (36)14863 (32)
 Obese5895 (42)6789 (34)3457 (28)16141 (35)
Dialysis modality (n, %)
 Peritoneal dialysis12 494 (100)12 94 (26)
 Haemodialysis
  Facility haemodialysis13 819 (97)20 578 (99.8)34 397 (73)
  Home haemodialysis479 (3)42 (0.2)521 (1)
Smoking status (n, %)
 Non-smoker6690 (48)9568 (47)6311 (51)22 569 (48)
 Current smoker1570 (11)2784 (14)1323 (11)5677 (12)
 Ex-smoker5797 (41)7980 (39)4728 (38)18 505 (40)
Comorbidities
 Chronic lung disease (n, %)1705 (12)3053 (15)1069 (9)5827 (12)
 Coronary artery disease (n, %)4637 (33)7426 (36)3284 (26)15 347 (33)
 Peripheral vascular disease (n, %)2310 (16)3964 (19)1647 (13)7921 (17)
 Cerebrovascular disease (n, %)1434 (10)2391 (12)1099 (9)4924 (10)
 Diabetes mellitus (n, %)
  Type 1519 (4)983 (5)711 (6)2213 (5)
  Type 26817 (48)9920 (48)4905 (39)21 642 (46)
 Cancer (n, %)1743 (12)2688 (13)1056 (9)5487 (12)
Late nephrologist referral (n, %)799 (6)7215 (35)1294 (11)9308 (20)
Cause of kidney failure (n, %)
 Diabetic nephropathy5573 (39)8110 (40)4280 (34)17 963 (38)
 Glomerular kidney disease2584 (18)3713 (18)2983 (24)9280 (20)
 Hypertension nephrosclerosis2048 (14)2855 (14)1817 (15)6720 (14)
 Familial/genetic kidney disease1481 (10)687 (3)1063 (9)3231 (7)
 Tubulointerstitial disease1310 (9)1675 (8)1121 (9)4106 (9)
 Others1214 (9)3431 (17)1173 (9)5818 (12)
Geographical location (n, %)
 Urban9371 (66)13 421 (66)8739 (70)31 531 (67)
 Regional3900 (28)5411 (27)3186 (26)12 497 (27)
 Remote909 (6)1602 (8)499 (4)3010 (6)
Socio-economic status (n, %)
 Low4258 (30)6333 (31)3909 (32)14 500 (31)
 Mid5444 (38)7715 (38)4707 (38)17 866 (38)
 High4469 (32)6379 (31)3804 (31)14 651 (31)
State/territory at dialysis initiation (n, %)
 New South Wales3685 (26)6027 (29)4591 (37)14 303 (30)
 Queensland2933 (21)4156 (20)2383 (19)9472 (20)
 Victoria3770 (26)4678 (23)2937 (24)11 385 (24)
 Australian Capital Territory301 (2)518 (3)162 (1)981 (2)
 South Australia1316 (9)1246 (6)816 (7)3378 (7)
 Western Australia1404 (10)2573 (13)1216 (10)5193 (11)
 Northern Territory605 (4)1017 (5)159 (1)1781 (4)
 Tasmania284 (2)405 (2)230 (2)919 (2)
Era (n, %)
 2005–103957 (28)6249 (30)3318 (27)13 524 (29)
 2011–164702 (33)6246 (30)4244 (34)15 192 (32)
 2017–225639 (39)8125 (40)4932 (40)18 696 (39)
Pre-emptive transplant (n, %)78 (0.5)125 (0.6)91 (0.7)294 (0.6)
Centre-level characteristics
Number of centres10110467106
Transplant centre (n, %)17 (17)17 (16)16 (24)18 (17)
Centre size (median, IQR)
 Incidence dialysis patient/year57 (31–101)62 (38–101)78 (45–113)64 (38–106)
 Incidence PD patient/year13 (5–27)15 (6–27)22 (7–39)16 (7–30)
 Incidence HD patient/year44 (24–70)46 (28–71)48 (31–70)46 (28–70)

aIndigenous—Aboriginal and Torres Strait Islander, Polynesian.

Mortality rates

Among all incident patients, 22 838 (48%) patients died in the follow-up period, and 8170 (17%) died from dialysis withdrawal. The all-cause mortality rate was 138/1000 (95% CI 137–140/1000) patient-years, and the withdrawal-related mortality rate was 49/1000 (95% CI 48–51/1000) patient-years. Of the 8170 patients who died from dialysis withdrawal, 2382 (29%) were initiated via HD-AVF, 4007 (49%) were initiated via HD-CVC, and 1781 (22%) were initiated via PD-PDC. Figure 2 shows the proportion of incident patients on dialysis who withdrew from dialysis, stratified by dialysis vintage.

Proportion of incident patients on dialysis who withdrew from dialysis, stratified by initial dialysis access and time from dialysis initiation.
Figure 2:

Proportion of incident patients on dialysis who withdrew from dialysis, stratified by initial dialysis access and time from dialysis initiation.

Association between dialysis access and dialysis withdrawal: HD-CVC vs HD-AVF

The propensity score-matched, paired cohort comprised 22 744 incident patients, with 11 372 pairs of patients commenced on HD-CVC and HD-AVF. Standardized percentage bias is shown in Supplementary Fig. 1a. Compared with patients who were initiated on HD-AVF, patients on HD-CVC were more likely to withdraw from dialysis in the first 3 years after dialysis initiation with reduced magnitude over time [Model 3 adjusted HR (aHR) for 0–6 months: 2.43, 95% CI 1.95–3.02; >6–12 months: 2.06, 1.67–2.53; >1–3 years: 1.57, 1.40–1.76]. No difference was observed after 3 years post-dialysis initiation (aHR 1.06, 0.97–1.15) (Table 2, Fig. 3). Analysis estimates for Models 3, 4, and 5 were similar. Figure 4a shows the continuous aHR for dialysis withdrawal comparing HD-CVC and HD-AVF, up to 10 years after dialysis initiation. Similar patterns were observed in the competing risk analyses (Supplementary Fig. 2).

Cox regression analysis of the association between types of dialysis access and dialysis withdrawal, matched by propensity scores.
Figure 3:

Cox regression analysis of the association between types of dialysis access and dialysis withdrawal, matched by propensity scores.

Continuous, adjusted cause-specific hazard ratios (solid lines; shaded areas are 95% CIs) up to 10 years after dialysis initiation, derived from the flexible parametric proportional hazards model. (a) Patients initiated on haemodialysis via central venous catheter (CVC) to patients initiated on haemodialysis via arteriovenous fistula (AVF). (b) Patients initiated on peritoneal dialysis (PD) to patients initiated on haemodialysis via central venous catheter (CVC). (c) Patients initiated on haemodialysis via arteriovenous fistula (AVF) to patients initiated on peritoneal dialysis (PD).
Figure 4:

Continuous, adjusted cause-specific hazard ratios (solid lines; shaded areas are 95% CIs) up to 10 years after dialysis initiation, derived from the flexible parametric proportional hazards model. (a) Patients initiated on haemodialysis via central venous catheter (CVC) to patients initiated on haemodialysis via arteriovenous fistula (AVF). (b) Patients initiated on peritoneal dialysis (PD) to patients initiated on haemodialysis via central venous catheter (CVC). (c) Patients initiated on haemodialysis via arteriovenous fistula (AVF) to patients initiated on peritoneal dialysis (PD).

Table 2:

Propensity score-matched Cox regression analysis examining the associations between dialysis access and dialysis withdrawal.

 Model 1 HR (95% CI)Model 2 HR (95% CI)Model 3 HR (95% CI)Model 4 HR (95% CI)Model 5 HR (95% CI)
HD-CVC vs HD-AVF
 0–6 months2.47 (1.98–3.08)2.37 (1.90–2.96)2.43 (1.95–3.02)2.41 (1.93–3.01)2.27 (1.75–2.95)
 >6–12 months2.04 (1.65–2.51)2.00 (1.63–2.47)2.06 (1.67–2.53)2.06 (1.67–2.54)2.00 (1.56–2.56)
 >1–3 years1.53 (1.36–1.72)1.53 (1.36–1.72)1.57 (1.40–1.76)1.57 (1.40–1.77)1.60 (1.44–1.87)
 >3 years1.00 (0.92–1.09)1.04 (0.96–1.14)1.06 (0.97–1.15)1.07 (0.98–1.16)1.07 (0.98–1.18)
HD-CVC vs PD-PDC
 0–6 months2.89 (2.22–3.74)2.70 (2.08–3.50)2.78 (2.14–3.61)2.74 (2.11–3.57)2.83 (2.05–3.91)
 >6–12 months1.90 (1.51–2.39)1.86 (1.48–2.35)1.90 (1.51–2.40)1.87 (1.48–2.36)1.81 (1.37–2.39)
 >1–3 years1.25 (1.10–1.40)1.25 (1.10–1.40)1.26 (1.12–1.42)1.25 (1.10–1.41)1.22 (1.06–1.40)
 >3 years0.88 (0.80–0.96)0.94 (0.85–1.03)0.94 (0.85–1.03)0.94 (0.85–1.03)0.93 (0.83–1.03)
HD-AVF vs PD-PDC
 0–6 months1.19 (0.87–1.63)1.18 (0.86–1.62)1.16 (0.85–1.59)1.11 (0.81–1.53)1.36 (0.92–2.01)
 >6–12 months0.93 (0.71–1.21)0.92 (0.71–1.20)0.91 (0.70–1.18)0.89 (0.68–1.17)0.92 (0.66–1.29)
 >1–3 years0.76 (0.66–0.86)0.76 (0.66–0.86)0.75 (0.66–0.85)0.73 (0.64–0.84)0.75 (0.64–0.88)
 >3 years0.90 (0.82–0.99)0.94 (0.86–1.03)0.93 (0.84–1.01)0.92 (0.83–1.01)0.93 (0.84–1.03)
 Model 1 HR (95% CI)Model 2 HR (95% CI)Model 3 HR (95% CI)Model 4 HR (95% CI)Model 5 HR (95% CI)
HD-CVC vs HD-AVF
 0–6 months2.47 (1.98–3.08)2.37 (1.90–2.96)2.43 (1.95–3.02)2.41 (1.93–3.01)2.27 (1.75–2.95)
 >6–12 months2.04 (1.65–2.51)2.00 (1.63–2.47)2.06 (1.67–2.53)2.06 (1.67–2.54)2.00 (1.56–2.56)
 >1–3 years1.53 (1.36–1.72)1.53 (1.36–1.72)1.57 (1.40–1.76)1.57 (1.40–1.77)1.60 (1.44–1.87)
 >3 years1.00 (0.92–1.09)1.04 (0.96–1.14)1.06 (0.97–1.15)1.07 (0.98–1.16)1.07 (0.98–1.18)
HD-CVC vs PD-PDC
 0–6 months2.89 (2.22–3.74)2.70 (2.08–3.50)2.78 (2.14–3.61)2.74 (2.11–3.57)2.83 (2.05–3.91)
 >6–12 months1.90 (1.51–2.39)1.86 (1.48–2.35)1.90 (1.51–2.40)1.87 (1.48–2.36)1.81 (1.37–2.39)
 >1–3 years1.25 (1.10–1.40)1.25 (1.10–1.40)1.26 (1.12–1.42)1.25 (1.10–1.41)1.22 (1.06–1.40)
 >3 years0.88 (0.80–0.96)0.94 (0.85–1.03)0.94 (0.85–1.03)0.94 (0.85–1.03)0.93 (0.83–1.03)
HD-AVF vs PD-PDC
 0–6 months1.19 (0.87–1.63)1.18 (0.86–1.62)1.16 (0.85–1.59)1.11 (0.81–1.53)1.36 (0.92–2.01)
 >6–12 months0.93 (0.71–1.21)0.92 (0.71–1.20)0.91 (0.70–1.18)0.89 (0.68–1.17)0.92 (0.66–1.29)
 >1–3 years0.76 (0.66–0.86)0.76 (0.66–0.86)0.75 (0.66–0.85)0.73 (0.64–0.84)0.75 (0.64–0.88)
 >3 years0.90 (0.82–0.99)0.94 (0.86–1.03)0.93 (0.84–1.01)0.92 (0.83–1.01)0.93 (0.84–1.03)

Model 1: univariate.

Model 2: Model 1 + non-modifiable variables (age, gender, ethnicity).

Model 3: Model 2 + medical variables [late nephrology referral, body mass index, comorbid medical conditions (coronary artery disease, cerebrovascular disease, chronic lung disease, peripheral vascular disease, cancer, diabetes mellitus, primary kidney disease)].

Model 4: Model 3 + social variables (era, geographical location, socio-economic status, Australian state at time of dialysis initiation).

Model 5: Model 4 + centre-level characteristics (transplant centre, centre size).

Final model: Model 3 (bold).

Table 2:

Propensity score-matched Cox regression analysis examining the associations between dialysis access and dialysis withdrawal.

 Model 1 HR (95% CI)Model 2 HR (95% CI)Model 3 HR (95% CI)Model 4 HR (95% CI)Model 5 HR (95% CI)
HD-CVC vs HD-AVF
 0–6 months2.47 (1.98–3.08)2.37 (1.90–2.96)2.43 (1.95–3.02)2.41 (1.93–3.01)2.27 (1.75–2.95)
 >6–12 months2.04 (1.65–2.51)2.00 (1.63–2.47)2.06 (1.67–2.53)2.06 (1.67–2.54)2.00 (1.56–2.56)
 >1–3 years1.53 (1.36–1.72)1.53 (1.36–1.72)1.57 (1.40–1.76)1.57 (1.40–1.77)1.60 (1.44–1.87)
 >3 years1.00 (0.92–1.09)1.04 (0.96–1.14)1.06 (0.97–1.15)1.07 (0.98–1.16)1.07 (0.98–1.18)
HD-CVC vs PD-PDC
 0–6 months2.89 (2.22–3.74)2.70 (2.08–3.50)2.78 (2.14–3.61)2.74 (2.11–3.57)2.83 (2.05–3.91)
 >6–12 months1.90 (1.51–2.39)1.86 (1.48–2.35)1.90 (1.51–2.40)1.87 (1.48–2.36)1.81 (1.37–2.39)
 >1–3 years1.25 (1.10–1.40)1.25 (1.10–1.40)1.26 (1.12–1.42)1.25 (1.10–1.41)1.22 (1.06–1.40)
 >3 years0.88 (0.80–0.96)0.94 (0.85–1.03)0.94 (0.85–1.03)0.94 (0.85–1.03)0.93 (0.83–1.03)
HD-AVF vs PD-PDC
 0–6 months1.19 (0.87–1.63)1.18 (0.86–1.62)1.16 (0.85–1.59)1.11 (0.81–1.53)1.36 (0.92–2.01)
 >6–12 months0.93 (0.71–1.21)0.92 (0.71–1.20)0.91 (0.70–1.18)0.89 (0.68–1.17)0.92 (0.66–1.29)
 >1–3 years0.76 (0.66–0.86)0.76 (0.66–0.86)0.75 (0.66–0.85)0.73 (0.64–0.84)0.75 (0.64–0.88)
 >3 years0.90 (0.82–0.99)0.94 (0.86–1.03)0.93 (0.84–1.01)0.92 (0.83–1.01)0.93 (0.84–1.03)
 Model 1 HR (95% CI)Model 2 HR (95% CI)Model 3 HR (95% CI)Model 4 HR (95% CI)Model 5 HR (95% CI)
HD-CVC vs HD-AVF
 0–6 months2.47 (1.98–3.08)2.37 (1.90–2.96)2.43 (1.95–3.02)2.41 (1.93–3.01)2.27 (1.75–2.95)
 >6–12 months2.04 (1.65–2.51)2.00 (1.63–2.47)2.06 (1.67–2.53)2.06 (1.67–2.54)2.00 (1.56–2.56)
 >1–3 years1.53 (1.36–1.72)1.53 (1.36–1.72)1.57 (1.40–1.76)1.57 (1.40–1.77)1.60 (1.44–1.87)
 >3 years1.00 (0.92–1.09)1.04 (0.96–1.14)1.06 (0.97–1.15)1.07 (0.98–1.16)1.07 (0.98–1.18)
HD-CVC vs PD-PDC
 0–6 months2.89 (2.22–3.74)2.70 (2.08–3.50)2.78 (2.14–3.61)2.74 (2.11–3.57)2.83 (2.05–3.91)
 >6–12 months1.90 (1.51–2.39)1.86 (1.48–2.35)1.90 (1.51–2.40)1.87 (1.48–2.36)1.81 (1.37–2.39)
 >1–3 years1.25 (1.10–1.40)1.25 (1.10–1.40)1.26 (1.12–1.42)1.25 (1.10–1.41)1.22 (1.06–1.40)
 >3 years0.88 (0.80–0.96)0.94 (0.85–1.03)0.94 (0.85–1.03)0.94 (0.85–1.03)0.93 (0.83–1.03)
HD-AVF vs PD-PDC
 0–6 months1.19 (0.87–1.63)1.18 (0.86–1.62)1.16 (0.85–1.59)1.11 (0.81–1.53)1.36 (0.92–2.01)
 >6–12 months0.93 (0.71–1.21)0.92 (0.71–1.20)0.91 (0.70–1.18)0.89 (0.68–1.17)0.92 (0.66–1.29)
 >1–3 years0.76 (0.66–0.86)0.76 (0.66–0.86)0.75 (0.66–0.85)0.73 (0.64–0.84)0.75 (0.64–0.88)
 >3 years0.90 (0.82–0.99)0.94 (0.86–1.03)0.93 (0.84–1.01)0.92 (0.83–1.01)0.93 (0.84–1.03)

Model 1: univariate.

Model 2: Model 1 + non-modifiable variables (age, gender, ethnicity).

Model 3: Model 2 + medical variables [late nephrology referral, body mass index, comorbid medical conditions (coronary artery disease, cerebrovascular disease, chronic lung disease, peripheral vascular disease, cancer, diabetes mellitus, primary kidney disease)].

Model 4: Model 3 + social variables (era, geographical location, socio-economic status, Australian state at time of dialysis initiation).

Model 5: Model 4 + centre-level characteristics (transplant centre, centre size).

Final model: Model 3 (bold).

Association between dialysis access and dialysis withdrawal: HD-CVC vs PD-PDC

The propensity score-matched, paired cohort comprised 20 146 incident patients, with 10 073 pairs of patients commenced on HD-CVC and PD-PDC. Standardized percentage bias is shown in Supplementary Fig. 1b. Compared with patients who were initiated on PD-PDC, patients on HD-CVC were more likely to withdraw from dialysis in the first 3 years after dialysis initiation, with the greatest magnitude in the first 6 months (Model 3 aHR for 0–6 months: 2.78, 95% CI 2.14–3.61; >6–12 months: 1.90, 1.51–2.40; >1–3 years: 1.26, 1.12–1.42). No difference was observed after 3 years post-dialysis initiation (aHR 0.94, 0.85–1.03) (Table 2, Fig. 2). Analysis estimates for Models 3, 4, and 5 were similar. Figure 4b shows the continuous aHR for dialysis withdrawal comparing HD-CVC and PD-PDC, up to 10 years after dialysis initiation. Similar patterns were observed in the competing risk analyses (Supplementary Fig. 2).

Association between dialysis access and dialysis withdrawal: HD-AVF vs PD-PDC

The propensity score-matched, paired cohort comprised 19 864 incident patients, with 9932 pairs of patients commenced on HD-AVF and PD-PDC. Standardized percentage bias is shown in Supplementary Fig. 1c. Compared with patients who were initiated via PD-PDC catheter, patients on HD-AVF were less likely to withdraw from dialysis between >1 and 3 years after dialysis initiation (Model 3 aHR 0.75, 95% CI 0.66–0.85). This was not apparent for other time periods (Table 2, Fig. 2). Analysis estimates for Models 3, 4, and 5 were similar. Figure 4c shows the flexible parametric survival plot showing the continuous aHR for dialysis withdrawal deaths comparing HD-AVF and PD-PDC, up to 10 years after dialysis initiation. Similar patterns were observed in the competing risk analyses (Supplementary Fig. 2).

Interactions between dialysis access with sex, age or late referral for dialysis withdrawal

Of the 8170 patients who died from dialysis withdrawal, 4957 (61%) were men, and the mean (SD) age at time of dialysis initiation was 69.9 (±11.3) years. There was no interaction between dialysis access type and age or sex for dialysis withdrawal, across all time periods post-dialysis initiation. Inconsistent interaction was observed between dialysis access type and late referral for dialysis withdrawal (Table 3).

Table 3:

Interactive effects between dialysis access with age, sex and late referral for dialysis withdrawal (Model 3).

 HD-CVC vs HD-AVFHD-CVC vs PD -PDCHD-AVF vs PD-PDC
Interaction between dialysis access and age (Pinteraction)
 0–6 months0.610.850.62
 >6–12 months0.060.480.75
 >1–3 years0.530.750.82
 >3 years0.570.980.78
Interaction between dialysis access and sex (Pinteraction)
 0–6 months0.570.790.57
 >6–12 months0.600.050.17
 >1–3 years0.820.690.52
 >3 years0.390.100.35
Interaction between dialysis access and late referral (Pinteraction)
 0–6 months0.060.280.02
 >6–12 months0.030.110.61
 >1–3 years0.080.360.11
 >3 years0.120.600.52
 HD-CVC vs HD-AVFHD-CVC vs PD -PDCHD-AVF vs PD-PDC
Interaction between dialysis access and age (Pinteraction)
 0–6 months0.610.850.62
 >6–12 months0.060.480.75
 >1–3 years0.530.750.82
 >3 years0.570.980.78
Interaction between dialysis access and sex (Pinteraction)
 0–6 months0.570.790.57
 >6–12 months0.600.050.17
 >1–3 years0.820.690.52
 >3 years0.390.100.35
Interaction between dialysis access and late referral (Pinteraction)
 0–6 months0.060.280.02
 >6–12 months0.030.110.61
 >1–3 years0.080.360.11
 >3 years0.120.600.52
Table 3:

Interactive effects between dialysis access with age, sex and late referral for dialysis withdrawal (Model 3).

 HD-CVC vs HD-AVFHD-CVC vs PD -PDCHD-AVF vs PD-PDC
Interaction between dialysis access and age (Pinteraction)
 0–6 months0.610.850.62
 >6–12 months0.060.480.75
 >1–3 years0.530.750.82
 >3 years0.570.980.78
Interaction between dialysis access and sex (Pinteraction)
 0–6 months0.570.790.57
 >6–12 months0.600.050.17
 >1–3 years0.820.690.52
 >3 years0.390.100.35
Interaction between dialysis access and late referral (Pinteraction)
 0–6 months0.060.280.02
 >6–12 months0.030.110.61
 >1–3 years0.080.360.11
 >3 years0.120.600.52
 HD-CVC vs HD-AVFHD-CVC vs PD -PDCHD-AVF vs PD-PDC
Interaction between dialysis access and age (Pinteraction)
 0–6 months0.610.850.62
 >6–12 months0.060.480.75
 >1–3 years0.530.750.82
 >3 years0.570.980.78
Interaction between dialysis access and sex (Pinteraction)
 0–6 months0.570.790.57
 >6–12 months0.600.050.17
 >1–3 years0.820.690.52
 >3 years0.390.100.35
Interaction between dialysis access and late referral (Pinteraction)
 0–6 months0.060.280.02
 >6–12 months0.030.110.61
 >1–3 years0.080.360.11
 >3 years0.120.600.52

Sensitivity analysis

In the sensitivity analysis combining both AVF and AVG as a single group, the aHRs for dialysis withdrawal were similar to the primary analysis when compared with HD-CVC. There was no association observed comparing PD-PDC and HD-AVF/AVG for dialysis withdrawal, regardless of dialysis vintage (Supplementary Table 3). The FDR assessment showed wider confidence intervals, but the associations remained statistically significant (Supplementary Table 4).

DISCUSSION

In this contemporaneous cohort study of incident patients with kidney failure in Australia, patients who were initiated on HD-CVC were more likely to experience dialysis withdrawal in the first 3 years after dialysis initiation, compared with patients on HD-AVF or PD-PDC. The magnitudes of the increased risks reduced exponentially over time. These observations provide a greater understanding of dialysis access and associated survival outcomes and offer guidance when choosing dialysis treatment, especially when life expectancy is limited.

Traditionally, AVF was the preferred vascular access for patients on haemodialysis with putative benefits [6, 8, 22–26]. Although the 2019 KDOQI guidelines did recognize the lack of evidence in mortality benefit for vascular access conversion in the first year of dialysis initiation, the guidelines still recommended that patients commenced on HD-CVC should convert to either an AVF or AVG if possible [8]. In our study, patients who were initiated on HD-CVC were twice as likely to withdraw from dialysis in the first 12 months of dialysis initiation compared with patients who were initiated on HD-AVF or PD-PDC. Survey studies from Canada and Ireland reported that patients on HD-CVC experienced a lower dialysis-related symptom burden and had better physical functioning scores compared with patients on HD-AVF [27, 28]. Delaying conversion from CVC to AVF/AVG/PDC may be appropriate in selected patients to prevent unnecessary medical procedures and clinical burden. Further studies assessing the harms and benefits of delaying dialysis access conversion are needed for the formulation of an end-stage kidney disease life plan and provision of individualized care, as suggested by the 2019 KDOQI guidelines [8].

Our study showed that the time between dialysis initiation and withdrawal for patients who commenced HD-CVC could be short, with the greatest hazard in the first 6 months after dialysis initiation. Although a time-limited dialysis trial for patients with uncertain prognosis may contribute to the early dialysis withdrawal [29], ANZDATA intends to only include patients receiving maintenance dialysis. Hence, patients with acute kidney injury on short-term dialysis were not reported to ANZDATA. During this uncertain period, advance care planning through the shared decision-making process is crucial. While on dialysis, patients may experience a significant symptom burden [30–33]. Addressing these symptoms may delay or prevent patients from dialysis withdrawal [30, 34]. Early involvement of a kidney supportive care (or palliative care) service may assist in the facilitation of the serious illness conversations, management of symptom burdens, and improvement of quality of life [34, 35]. Unfortunately, ANZDATA does not collect information on patient-reported outcomes to further assess the symptom burdens or quality of life.

Considering the likelihood of death from early dialysis withdrawal was significantly higher in patients who commenced HD-CVC, conservative kidney management (CKM, or non-dialysis pathway) may be a suitable alternative for certain patient groups [36]. Our study did not show any interactions of age and sex with dialysis access type in the association with dialysis withdrawal. Commencing HD-CVC may be a surrogate marker for frailty, psychosocial status, and health literacy, which are associated with increased mortality [37–39]. A previous ANZDATA study showed that older age, late nephrologist referral, and comorbid medical conditions were associated with dialysis withdrawal in the first 12 months after dialysis initiation [5]. More detailed studies on the predicting factors (including psychosocial wellbeing, socio-economic determinants, and severity of comorbid medical conditions) and their interactions with HD-CVC for early dialysis withdrawal will likely help identifying patients who may benefit from CKM, instead of dialysis initiation via CVC followed by early dialysis withdrawal. However, ANZDATA does not include patients receiving CKM to provide further insights for this patient group.

Mortality difference between PD and haemodialysis has constantly been debated despite numerous observational studies failing to provide a definitive answer [40–43]. Our study showed that withdrawal-related mortality differed significantly when comparing PD-PDC with HD-AVF versus HD-CVC, yet haemodialysis vascular access often was not differentiated in observational studies [8, 43]. In our study, patients who were commenced on dialysis via HD-AVF had a reduced risk of dialysis withdrawal 1–3 years after dialysis initiation, compared with patients commenced on PD-PDC. This may reflect PD discontinuation without transfer to haemodialysis. ANZDATA does not collect reasons for PD discontinuation in patients not transferred to haemodialysis; hence, such events were not examined further in our study.

There are several inherent limitations with observational registry data. First, ANZDATA collects dialysis access through the end-of-year survey reporting the initial and last dialysis access during the survey year. The duration of each dialysis access is not specified. Therefore, recall bias might occur, and the reported dialysis access might not be the primary dialysis access during the survey period. Second, dialysis withdrawal was reported by the treating centres, and only a single cause of death could be reported. The registry does not verify the accuracy of these causes, and misclassification bias of the cause of death is possible. Third, there are unmeasured and residual confounders which may be different between patients who were initiated on different dialysis access types. Information on severity of comorbid medical conditions, reasons for dialysis initiation and modality selection, psychosocial factors, functional status, and cognitive impairment is not collected by ANZDATA but might have modified the association between dialysis access and dialysis withdrawal.

In conclusion, initiating haemodialysis via CVC was associated with increased risks of dialysis withdrawal in the first 3 years of dialysis, compared with HD-AVF and PD-PDC, with the risks doubled in the first 12 months after dialysis initiation. Delaying the transition of dialysis access for patients initiated on HD-CVC and considering conservative kidney management with early involvement of kidney supportive care may minimize dialysis-associated psychosocial burdens and medical complications. Individualized treatment for kidney failure, including dialysis access choice, empowers clinicians and patients to balance the potential medical benefits and quality of life.

ACKNOWLEDGEMENTS

The authors thank the entire Australian and New Zealand Nephrology community (physicians, surgeons, database managers, nurses, and patients), which provides information to and maintains the ANZDATA Registry database, for their substantial contributions. The data reported here have been supplied by the ANZDATA Registry. The interpretation and reporting of these data are the responsibility of the authors and should not be seen as an official policy or interpretation of the ANZDATA Registry.

FUNDING

None.

AUTHORS’ CONTRIBUTIONS

All authors have contributed to this manuscript and approve of this submission. J.C., C.D., and W.L. participated in the design and analysis of this study. All authors participated in the interpretation of data and drafting/revising the paper.

DATA AVAILABILITY STATEMENT

The data underlying this article will be shared on reasonable request to the corresponding author.

CONFLICT OF INTEREST STATEMENT

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

REFERENCES

1.

Australian and New Zealand Dialysis and Transplant Registry
.
ANZDATA 46th Annual Report 2023. Chapter 3: Mortality of kidney failure with replacement therapy
.
Adelaide, Australia
:
Australian and New Zealand Dialysis and Transplant Registry
,
2023
.

2.

Ellwood
 
AD
,
Jassal
 
SV
,
Suri
 
RS
 et al.  
Early dialysis initiation and rates and timing of withdrawal from dialysis in Canada
.
Clin J Am Soc Nephrol
 
2013
;
8
:
265
70
.

3.

United States Renal Data System
.
End Stage Renal Disease. Chapter 6: Mortality
.
Bethesda, MD
:
National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
,
2023
.

4.

Chen
 
JHC
,
Lim
 
WH
,
Howson
 
P.
 
Changing landscape of dialysis withdrawal in patients with kidney failure: implications for clinical practice
.
Nephrology
 
2022
;
27
:
551
65
.

5.

Chen
 
JHC
,
Brown
 
MA
,
Jose
 
M
 et al.  
Temporal changes and risk factors for death from early withdrawal within 12 months of dialysis initiation—a cohort study
.
Nephrol Dial Transplant
 
2022
;
37
:
760
9
.

6.

Ravani
 
P
,
Palmer
 
SC
,
Oliver
 
MJ
 et al.  
Associations between hemodialysis access type and clinical outcomes: a systematic review
.
J Am Soc Nephrol
 
2013
;
24
:
465
73
.

7.

III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: Update 2000
.
Am J Kidney Dis
 
2001
;
37
:
S137
81
.

8.

Lok
 
CE
,
Huber
 
TS
,
Lee
 
T
 et al.  
KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update
.
Am J Kidney Dis
 
2020
;
75
:
S1
S164
. .

9.

Lee
 
T.
 
Fistula First Initiative: historical impact on vascular access practice patterns and influence on future vascular access care
.
Cardiovasc Eng Tech
 
2017
;
8
:
244
54
.

10.

Lomonte
 
C
,
Basile
 
C
,
Mitra
 
S
 et al.  
Should a fistula first policy be revisited in elderly haemodialysis patients?
 
Nephrol Dial Transplant
 
2019
;
34
:
1636
43
.

11.

Viecelli
 
AK
,
Lok
 
CE.
 
Hemodialysis vascular access in the elderly—getting it right
.
Kidney Int
 
2019
;
95
:
38
49
.

12.

Findlay
 
MD
,
Donaldson
 
K
,
Doyle
 
A
 et al.  
Factors influencing withdrawal from dialysis: a national registry study
.
Nephrol Dial Transplant
 
2016
;
31
:
2041
8
.

13.

Wetmore
 
JB
,
Yan
 
H
,
Gilbertson
 
DT
 et al.  
Factors associated with elective withdrawal of maintenance hemodialysis: a case-control analysis
.
Am J Nephrol
 
2020
;
51
:
227
36
.

14.

Lim
 
WH
,
Chen
 
JHC
,
Minas
 
K
 et al.  
Sex disparity in cause-specific and all-cause mortality among incident dialysis patients
.
Am J Kidney Dis
 
2023
;
81
:
156
167.e1
.

15.

von Elm
 
E
,
Altman
 
DG
,
Egger
 
M
 et al.  
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
.
Ann Intern Med
 
2007
;
147
:
573
7
.

18.

Smart
 
NA
,
Titus
 
TT.
 
Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review
.
Am J Med
 
2011
;
124
:
1073
1080.e2
.

19.

Australian and New Zealand Dialysis and Transplant Registry
.
ANZDATA 46th Annual Report 2023. Chapter 5: Peritoneal dialysis
.
Adelaide, Australia
:
Australia and New Zealand Dialysis and Transplant Registry
,
2023
.

20.

Royston
 
P
,
Parmar
 
MK.
 
Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects
.
Stat Med
 
2002
;
21
:
2175
97
.

21.

Fine
 
JP
,
Gray
 
RJ.
 
A proportional hazards model for the subdistribution of a competing risk
.
J Am Statist Assoc
 
1999
;
94
:
496
509
.

22.

Polkinghorne
 
KR
,
McDonald
 
SP
,
Atkins
 
RC
 et al.  
Vascular access and all-cause mortality: a propensity score analysis
.
J Am Soc Nephrol
 
2004
;
15
:
477
86
.

23.

Wasse
 
H
,
Speckman
 
RA
,
McClellan
 
WM.
 
Arteriovenous fistula use is associated with lower cardiovascular mortality compared with catheter use among ESRD patients
.
Semin Dial
 
2008
;
21
:
483
9
.

24.

Astor
 
BC
,
Eustace
 
JA
,
Powe
 
NR
 et al.  
Type of vascular access and survival among incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study
.
J Am Soc Nephrol
 
2005
;
16
:
1449
55
.

25.

Almasri
 
J
,
Alsawas
 
M
,
Mainou
 
M
 et al.  
Outcomes of vascular access for hemodialysis: a systematic review and meta-analysis
.
J Vasc Surg
 
2016
;
64
:
236
43
.

26.

Pisoni
 
RL
,
Arrington
 
CJ
,
Albert
 
JM
 et al.  
Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: an instrumental variable analysis
.
Am J Kidney Dis
 
2009
;
53
:
475
91
.

27.

Quinn
 
RR
,
Lamping
 
DL
,
Lok
 
CE
 et al.  
The Vascular Access Questionnaire: assessing patient-reported views of vascular access
.
J Vasc Access
 
2008
;
9
:
122
8
.

28.

Maguire
 
IC
,
Browne
 
LD
,
Dawood
 
M
 et al.  
Differential impact of central venous catheters versus arteriovenous fistulae on quality of life among Irish haemodialysis patients
.
Kidney360
 
2022
;
3
:
1065
72
.

29.

Scherer
 
JS
,
Holley
 
JL.
 
The role of time-limited trials in dialysis decision making in critically ill patients
.
Clin J Am Soc Nephrol
 
2016
;
11
:
344
53
.

30.

Mehrotra
 
R
,
Davison
 
SN
,
Farrington
 
K
 et al.  
Managing the symptom burden associated with maintenance dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
.
Kidney Int
 
2023
;
104
:
441
54
.

31.

Davison
 
SN
,
Jhangri
 
GS.
 
Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients
.
J Pain Symptom Manage
 
2010
;
39
:
477
85
.

32.

Palmer
 
S
,
Vecchio
 
M
,
Craig
 
JC
 et al.  
Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies
.
Kidney Int
 
2013
;
84
:
179
91
.

33.

King-Wing Ma
 
T
,
Kam-Tao Li
 
P.
 
Depression in dialysis patients
.
Nephrology (Carlton)
 
2016
;
21
:
639
46
.

34.

Gelfand
 
SL
,
Scherer
 
JS
,
Koncicki
 
HM.
 
Kidney Supportive Care: Core Curriculum 2020
.
Am J Kidney Dis
 
2020
;
75
:
793
806
.

35.

Davison
 
SN
,
Pommer
 
W
,
Brown
 
MA
 et al.  
Conservative kidney management and kidney supportive care: core components of integrated care for people with kidney failure
.
Kidney Int
 
2024
;
105
:
35
45
.

36.

Li
 
KC
,
Brown
 
MA.
 
Conservative kidney management: when, why, and for whom?
 
Semin Nephrol
 
2023
;
43
:
151395
.

37.

Woo
 
K
,
Gascue
 
L
,
Norris
 
K
 et al.  
Patient frailty and functional use of hemodialysis vascular access: a retrospective study of the US Renal Data System
.
Am J Kidney Dis
 
2022
;
80
:
30
45
.

38.

Krishnasamy
 
R
,
Jegatheesan
 
D
,
Lawton
 
P
 et al.  
Socioeconomic status and dialysis quality of care
.
Nephrology
 
2020
;
25
:
421
8
.

39.

Zavacka
 
M
,
Skoumalova
 
I
,
Geckova
 
AM
 et al.  
Does health literacy of hemodialyzed patients predict the type of their vascular access? A cross-sectional study on Slovak hemodialyzed population
.
Int J Environ Res Public Health
 
2020
;
17
 
675
.

40.

Wong
 
B
,
Ravani
 
P
,
Oliver
 
MJ
 et al.  
Comparison of patient survival between hemodialysis and peritoneal dialysis among patients eligible for both modalities
.
Am J Kidney Dis
 
2018
;
71
:
344
51
.

41.

Lukowsky
 
LR
,
Mehrotra
 
R
,
Kheifets
 
L
 et al.  
Comparing mortality of peritoneal and hemodialysis patients in the first 2 years of dialysis therapy: a marginal structural model analysis
.
Clin J Am Soc Nephrol
 
2013
;
8
:
619
28
.

42.

Wang
 
V
,
Coffman
 
CJ
,
Sanders
 
LL
 et al.  
Comparing mortality of peritoneal and hemodialysis patients in an era of Medicare payment reform
.
Med Care
 
2021
;
59
:
155
62
.

43.

Marshall
 
MR.
 
The benefit of early survival on PD versus HD—why this is (still) very important
.
Perit Dial Int
 
2020
;
40
:
405
18
.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary data

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.